Premier Update: Successful Pilot Study

RNS Number : 3253H

Deltex Medical Group PLC

19 June 2013

 



Deltex Medical Group plc

("Deltex Medical" or "the Company")

Premier project: pilot study shows large benefits from ODM and enhanced recovery

Expected to drive further studies across the US

19 June 2013 - Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), which measures blood flow in real time enabling fluid level optimisation to enhance recovery after surgery and in intensive care, announces the presentation at Premier Inc's annual Breakthroughs conference of positive results from a pilot study undertaken in colorectal surgery at Duke University Hospital, North Carolina.

The publication of these results, which were compiled during 2012, is expected to expedite selection of suitable sites to participate in the next phase of Deltex's collaboration with Premier as well as supporting its engagement with other US hospitals.

Patients treated within the enhanced recovery programme, which includes use of ODM to manage fluids during surgery, compared to those not so treated:

-           went home 2.4 days (29%) sooner (6 days rather than 8.4 days)

-           incurred $3,640 (16%) lower hospital costs ($19,344 v $22,984)

-           56% reduction in readmissions within 30 days from 20.2% to 8.8%

Higher savings of over $5,000 per patient were found in those patients where compliance with the enhanced recovery protocol was highest: such patients experienced the shortest lengths of stay and lowest levels of readmissions.

The reported cost savings comprise only costs incurred by the hospital allocated directly to the patient. They exclude additional savings to payers from reduced payments to physicians and also exclude the costs to hospitals of treating unfunded readmissions.

Premier Inc's Breakthroughs conference in San Antonio, Texas was attended by circa 4,000 clinical and management staff from Premier's membership, which includes around half the hospitals in the USA.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"We are pleased that Premier's economic analysis of the impact of Duke's implementation of an enhanced recovery programme using CardioQ-ODM is now in the public domain. In the shorter term we expect these highly positive results to expedite selection of suitable sites to participate in the next phase of our collaboration with Premier as well as supporting our engagement with other US hospitals. Each of the key outcomes of reduced hospital costs, reduced readmissions and improved outcomes are powerful drivers for changing care provision in large parts of the US healthcare system."

For further information, please contact:-

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Paul Mitchell, Finance Director
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie
Financial Public Relations
Newgate Threadneedle	020 7653 9850
Graham Herring
Caroline Evans-Jones
Heather Armstrong

Notes for Editors

Deltex Medical manufactures and markets CardioQ-ODMÔ Oesophageal Doppler Monitoring ('ODM') systems. ODM is the only therapy to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

The CardioQ-ODM has two distinct established clinical applications: firstly, to guide fluid management during surgery and secondly, to monitor cardiac output in critical care settings.

Surgical market

In March 2011 the National Institute for Health & Clinical Excellence ('NICE') recommended that CardioQ-ODM be considered for use in patients undergoing major and high risk surgery and in high risk patients undergoing intermediate risk surgery. NICE estimated the applicable number of such patients in the NHS in England alone to be over 800,000 each year. CardioQ-ODM has been shown to be effective in both elective and emergency surgery and with both general and regional anaesthetics. This recommendation was specific to CardioQ-ODM and was based on the robust evidence base that supports its use.

Subsequent to the NICE guidance, the NHS in England announced its selection of ODM as a high impact innovation to be rolled out across the system fully, at pace and scale with significant financial penalties starting in the NHS 2013/14 financial year ending 31 March 2014.

The NICE evaluation and recommendation confirms that the potential global market for CardioQ-ODM in surgery includes tens of millions of patients, even if confined to developed health economies: the most conservative estimate of the potential value of the market opportunity Deltex Medical has created is in excess of £1 billion per annum. The Company's core focus is on building market leading positions in this surgical market, both geographically and by type of surgery.

Critical care market

In critical care settings, well-equipped hospitals will often have more than one cardiac output monitoring technology available. In this environment, ODM's strengths are that it is quick to set up, easy to use, safe, low cost and the ideal technology for a patient in crisis requiring rapid or frequent intervention. The potential market for cardiac output monitoring in critical care is a fraction of the size of that for intra-operative fluid management.

Through the 2012 launch of the CardioQ-ODM+, Deltex Medical has added the Pulse Pressure Waveform Analysis ('PPWA') approach to monitoring cardiac output to ODM functionality. Doing this has improved Deltex Medical's offer for monitoring applications as well as providing doctors and nurses with a choice of clinical strategies appropriate to individual patients in different clinical settings.

Company goal

Our goal is to make oesophageal Doppler monitoring (ODM) a standard of care for patients in both these markets. We believe that, in most modern health systems, it is essential to have a robust evidence base of both clinical benefit and cost effectiveness in order to achieve system-wide adoption of a new medical technology. Deltex Medical is one of the very first medical technology companies to have completed the investment necessary to build such an evidence base: as a result, use of ODM during surgery has the proven potential to deliver both clinical and economic benefits that are material at each of patient, hospital and system level.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide and there are already over 2,800 CardioQ-ODM systems in use in hospitals worldwide. Distribution arrangements are in place in over 30 countries.

 

END

 

 

MSCBUGDLLGBBGXI